Insulino-mimetic effects of bis (alpha-furancarboxylato) oxovanadium (IV) in vitro.
- Author:
Yan-Rong LI
1
;
Li-Hui GAO
;
Yan-Lin MA
;
Yan-Fen NIU
;
Wei-Ping LIU
;
Ling LI
Author Information
1. Yunnan Pharmacological Laboratories of Natural Products, Kunming Medical College, Kunming 650031, China.
- Publication Type:Journal Article
- MeSH:
Adipocytes;
drug effects;
metabolism;
Animals;
Blood Glucose;
drug effects;
Hypoglycemic Agents;
pharmacology;
Insulin;
pharmacology;
Lipogenesis;
drug effects;
Male;
Organometallic Compounds;
pharmacology;
Rats;
Rats, Sprague-Dawley
- From:
Acta Pharmaceutica Sinica
2008;43(3):318-322
- CountryChina
- Language:Chinese
-
Abstract:
To study insulino-mimetic effects of bis(alpha-furancarboxylato) oxovanadium (IV) (BFOV), a orally active antidiabetic vanadyl complex, on glucose uptake and lipogenesis in isolated rat adipocytes were determined by using 2-deoxy-D-[3H]-glucose and D-[3H]-glucose, respectively. Lipolysis was assayed by free fatty acids (FFA) released from isolated rat adipocytes treated with epinephrine. The results showed that BFOV, similar to insulin, concentration-dependently significantly enhanced the uptake of 2-deoxy-D-[3H]-glucose and the transformation from D-[3H]-glucose to lipid in isolated rat adipocytes, with the EC50 values of (0.31 +/- 0.08) mmol L(-1) and (0.49 +/- 0.12) mmol L(-1), respectively. Moreover, BFOV markedly inhibited FFA release from isolated rat adipocytes treated with epinephrine, and the IC50 value was (0.30 +/- 0.20) mmol L(-1). BFOV had insulino-mimetic effects such as enhancing glucose uptake and lipogenesis, as well as inhibiting lipolysis.
